Cargando…

Mucopolysaccharidosis Type II: A Kenyan Case Series

Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mungai, L. N. Wainaina, Njeru, C. M., Nyamai, L. A., Maina, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716217/ https://www.ncbi.nlm.nih.gov/pubmed/34976050 http://dx.doi.org/10.1155/2021/2328402

Ejemplares similares

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Pregnancy in patients with mucopolysaccharidosis: a case series
por: Stewart, Fiona J., et al.
Publicado: (2016)

Cervical spondylolisthesis in mucopolysaccharidosis type II
por: Rossi, Alessandro, et al.
Publicado: (2022)

Variations in Mortality in Children Admitted with Pneumonia to Kenyan Hospitals
por: Ayieko, Philip, et al.
Publicado: (2012)

Biomarkers in patients with mucopolysaccharidosis type II and IV
por: Fujitsuka, Honoka, et al.
Publicado: (2019)

Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis
por: Rutten, M., et al.
Publicado: (2016)

Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl
por: Semyachkina, A. N., et al.
Publicado: (2019)

Asymptomatic gastrointestinal carriage of multidrug-resistant carbapenemase-producing Enterobacteriaceae among children under five years in a Kenyan hospital
por: Mutuma, Caroline Kirito, et al.
Publicado: (2023)

Clinical Presentation of Mucopolysaccharidosis Type II (Hunter's Syndrome)
por: Chinawa, JM, et al.
Publicado: (2012)

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
por: Burton, Barbara K., et al.
Publicado: (2020)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Airway management in mucopolysaccharidosis: a retrospective case series review
por: Tümer, Murat, et al.
Publicado: (2021)

Clinical and Molecular Characterization of Patients with Mucopolysaccharidosis Type I in an Algerian Series
por: Tebani, Abdellah, et al.
Publicado: (2016)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
por: Żuber, Zbigniew, et al.
Publicado: (2023)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
por: Raluy-Callado, Mireia, et al.
Publicado: (2013)

Atypical clinical presentation of mucopolysaccharidosis type II (Hunter syndrome): a case report
por: Shah, Gauri Shankar, et al.
Publicado: (2010)

Detailed pedigree analyses and prenatal diagnosis for a family with mucopolysaccharidosis type II
por: Zhang, Chuan, et al.
Publicado: (2021)

Prediction of phenotypic severity in mucopolysaccharidosis type IIIA
por: Knottnerus, Suzan J. G., et al.
Publicado: (2017)

Gene Therapy for Mucopolysaccharidosis Type II—A Review of the Current Possibilities
por: Zapolnik, Paweł, et al.
Publicado: (2021)

Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome
por: Chiong, Mary Anne D., et al.
Publicado: (2017)

Evaluation of the antibacterial activity of selected Kenyan medicinal plant extract combinations against clinically important bacteria
por: Odongo, Elizabeth A, et al.
Publicado: (2023)

Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
por: Salvalaio, Marika, et al.
Publicado: (2017)

Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
por: D’Avanzo, Francesca, et al.
Publicado: (2020)

The co-morbidity of DSM-V Gambling with DSM-V mental disorders and substance abuse in a Kenyan context of high risk schizophrenia
por: Ndetei, David M., et al.
Publicado: (2023)

Partnering Parasites: Evidence of Synergism between Heavy Schistosoma haematobium and Plasmodium Species Infections in Kenyan Children
por: Florey, Lia S., et al.
Publicado: (2012)

Safety Study of Sodium Pentosan Polysulfate for Adult Patients with Mucopolysaccharidosis Type II
por: Orii, Kenji, et al.
Publicado: (2019)

Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome)
por: Amartino, H., et al.
Publicado: (2014)

Molecular Characterization and Diversity of Bacteria Isolated from Fish and Fish Products Retailed in Kenyan Markets
por: Kyule, Domitila Ndinda, et al.
Publicado: (2022)

Rubella outbreak in a Rural Kenyan District, 2014: documenting the need for routine rubella immunization in Kenya
por: Njeru, Ian, et al.
Publicado: (2015)

Hip pathologies in mucopolysaccharidosis type III
por: Breyer, Sandra Rafaela, et al.
Publicado: (2021)

The neurobehavioral phenotype in mucopolysaccharidosis Type IIIB: An exploratory study
por: Shapiro, E., et al.
Publicado: (2016)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Mucopolysaccharidosis Type VI with Recurrent Chest Infection
por: Numan, Ashraf, et al.
Publicado: (2023)

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
por: Scarpa, Maurizio, et al.
Publicado: (2011)

An online survey of burden of illness in families with mucopolysaccharidosis type II children in the United States
por: Conner, Therese, et al.
Publicado: (2019)

Mucopolysaccharidosis Type I in Mexico: Case-Based Review
por: Cantú-Reyna, Consuelo, et al.
Publicado: (2023)

Novel therapies for mucopolysaccharidosis type III
por: Seker Yilmaz, Berna, et al.
Publicado: (2020)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g7i1e62a50psvafvolqe6m63ap